GBT Announces New Employment Inducement Grants
08 mars 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2021, the compensation committee of GBT’s board...
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
02 mars 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for the third annual Access to...
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 07h30 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on...
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
24 févr. 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020 Further established leadership in sickle cell disease (SCD) with data...
GBT Announces Participation in Upcoming Investor Conferences
19 févr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
17 févr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial...
GBT Announces New Employment Inducement Grants
05 févr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT’s board...
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
04 févr. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor) in...
Europäische Arzneimittelagentur genehmigt GBTs Antrag auf Marktzulassung für Oxbryta® (Voxelotor) zur Behandlung hämolytischer Anämie bei Sichelzellkrankheit
27 janv. 2021 12h46 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Kalifornien, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat heute bekanntgegeben, dass die Europäische Arzneimittelagentur (EMA) die...
L'Agence européenne des médicaments accepte la demande d'autorisation de mise sur le marché de GBT pour Oxbryta® (voxelotor) pour le traitement de l'anémie hémolytique dans la drépanocytose
27 janv. 2021 12h46 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 27 janv. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que l'Agence européenne des médicaments (EMA) avait...